Treatment of Climacteric and Postmenopausal Women with 17-β-Oestradiol and Norethisterone Acetate

Publisher Website
Google Scholar
Abstract
Thirty-four climacteric and 175 postmenopausal women were treated with 3 different preparations containing microcrystalline-17.beta.-estradiol and norethisterone acetate for climacteric symptoms and symptoms of estrogen deficiency. Fifty-six of the women (mean age 52 .+-. 5.2 yr) were treated with trisekvens (Group I), 131 women (mean age 53 .+-. 6.3 yr) with trisekvens forte (Group II) and 22 women (mean age 55.3 .+-. 5.2 yr) with estrofem forte (Group III). The patients were followed for 2 1/2-3 1/2 yr. Laboratory investigations included analysis of serum levels of triglycerides, cholesterol, Ca++, Na+, K+, alkaline phosphatase, creatinine, glucose, protein, albumin, haptoglobin, zinc sulfate, Fe, TIBC, n.e. bilirubin, ALAT [S-alanine aminotransferase] and ASAT [S-aspartate aminotransferase] and radioimmunoassay of serum levels of FSH [follicle stimulating hormone], LH [luteinizing hormone] and low polar estrogens (LPE). The therapy resulted in a disappearance of the climacteric symptoms (vasomotor symptoms, nervousness, irritability and sleep disturbances) and a considerable improvement of the symptoms caused by estrogen deficiency (atrophic changes in the vulva, the vaginal mucosa, urethra and bladder, and the state of the skin and skeletal mineral depots). Few side effects were observed. Thirty-four of the patients discontinued their treatment with the estrogen preparations: 14 changed to another type of estrogen and 20 stopped completely, 2 of them due to the discovery of mammary carcinoma. In general the estrogen preparations tested were well tolerated. The estrogen dose in trisekvens forte and estrofem forte seems to be sufficient for an adequate estrogen replacement therapy in climacteric and postmenopausal women.

This publication has 1 reference indexed in Scilit: